

27 Abstract

28 Objectives: Uncertainties in the pharmaceutical management of COVID-19 have led to reports of
29 increased indiscriminate uses of antibiotics. The aim of this study was to investigate this at a
30 national level in Pakistan.

31 Methods: We used IQVIA pharmaceutical sales volume data to analyze antibiotic consumption for
32 January-April 2020 in Pakistan. The consumption of 77 antibiotics for systemic use in 2020 was
33 calculated, and compared against the same period in 2019 to track changes in total consumption
34 and consumption pattern by six assigned therapeutic groups: tetracyclines, quinolones, beta-lactam
35 penicillins, other-beta-lactams, macrolides and “others” – comprising the remaining groups.

36 Results: The total consumption for January-April 2020 was 17.76 Defined Daily Doses per 1000
37 population per day (a 18.8% decrease from 2019). Quinolones, beta-lactam penicillins, other-beta-
38 lactams, and macrolides constituted 80% of total consumption. There were increases between
39 February-April 2020 of macrolides and “others”. In March 2020, 112768 more people consumed
40 a macrolide per day compared to March 2019; mostly azithromycin.

41 Conclusions: Total consumption decreased in the first four months of 2020 compared to 2019,
42 possibly arising from a combination of several pre-existing and concurrent economic conditions
43 as well as the lockdown situation. However, the results suggest an increase in the consumption of
44 the macrolide class of antibiotics during the early phase of COVID-19 in Pakistan.

45 Key terms: Antibiotic consumption, COVID-19, Pakistan, Macrolide, Azithromycin

46

47

48

49 **Introduction:** The non-evidence based use of antimicrobials during COVID-19 can accelerate
50 antimicrobial resistance (AMR) (1,2). COVID-19 was declared a pandemic by the World Health
51 Organization, WHO, on March 11, 2020, some three months after the December 2019 outbreak in
52 Wuhan. While there is as yet no definite therapeutic intervention specific for the causative agent,
53 Severe Acute Respiratory Syndrome Coronavirus 2, or SARS-CoV2, many medicines have been
54 used off-label, and are currently being evaluated in clinical trials (3,4). In early March 2020, the
55 social media promotion of putative therapeutic antimicrobials led to fears of an increase in
56 community antimicrobial sales and of self-medication which, in some cases, have already led to
57 deaths (5).

58 Pakistan, the world's fifth largest country by population, recorded its first COVID-19 case in
59 Karachi, Sindh Province, on February 26, 2020 (6). By April 6, there were only 3277 cases with
60 50 deaths (6). As of June 25, 2020, these have increased to 192970 cases with 3903 deaths (7).
61 Following the first two cases, one in Sindh province and the other in the neighboring Baluchistan
62 Province in late February, the Baluchistan Regional Government closed schools on February 27,
63 followed by Sindh (8). On March 21, Pakistan imposed a partial national lock-down, suspending
64 schools and public transportation with a stay-at-home order, with movement restricted but for
65 essential supplies and services (9). This was followed by the complete lockdown from April 1 to
66 May 8 (10).

67 In this study, we test the hypothesis that there was an increase in antibacterial consumption (AbC)
68 during the early stages of COVID-19 in Pakistan. The aim was to analyse AbC during the early
69 spread of COVID-19 in the country from January to April 2020 by comparing against consumption
70 during the same period in 2019, in order to map changes in amount and consumption patterns of
71 antibiotics.

72 **Methods:**

73 **Study design:** Using routinely collected pharmaceutical sales data, we analysed AbC in Pakistan
74 according to the well-established Anatomical Therapeutic Chemical/ Defined Daily Dose
75 (ATC/DDD) methodology (11,12).

76 Data source: We obtained pharmaceutical sale volume data for January-April of 2019 and 2020
77 for Pakistan from IQVIA database. This database comprised country-wide distributors
78 pharmaceutical sales volume data in units of product packs sold per month, excluding public
79 hospitals (13). We extracted data for all pharmaceutically used substances, or combinations, of the
80 ATC J01 class (anti-infectives for systemic use) comprising antibacterials only, excluding those
81 for the treatment of tuberculosis. The extracted dataset contained 77 antibiotics available as 4648
82 products (tablets, capsules, injections/infusions, suspensions/oral powders for suspension and oral
83 drops of different dosage form strengths).

84 The IQVIA dataset was reclassified into current (2019) ATC codes, and based on a preliminary
85 analysis of sale volumes, reclassified into six therapeutic groups: (I) J01A, tetracyclines, (II)
86 J01C, beta-lactams, penicillins (III) J01D, other beta-lactams, (IV) J01F, macrolides, (V) J01M,
87 quinolones, and (VI) “others”, consisting of eight sub-groups or individual antibiotics not already
88 classified.

89 Analysis: Data analysis was performed at the ATC level 3 (therapeutic groups) using two measures
90 of AbC: total consumption and consumption pattern. AbC was analysed as Defined Daily Doses
91 (DDD) per 1000 population per day, or DID (14). For this comparative analysis, we used the
92 estimated population for 2019 of 216565318 and factored in a 2.1% growth to give the population
93 for 2020 as 221113190 (15).

94 A monthly DID for each antibiotic was calculated from sale volumes using the formula:

95 $[\text{Monthly sale amount (mg)} \times 1000] / [\text{DDD (mg)} \times \text{days in the month} \times \text{study population}]$ (16);

96 where monthly sale amount = (Substance dosage form strength (mg/g) x unit pack-size x units
97 sold); and unit pack-size is the number of doses, or standard units, per pack. One standard unit was
98 a tablet, capsule, vial or ampoule. For oral suspensions or syrups meant for use in children, the
99 standard unit was 5 ml (17). For example, the unit pack-size for an oral liquid substance presented
100 as a 60 ml bottle was 60/5, or 12 standard units. With drops, the standard unit was adopted as 1.
101 Thus, a pediatric dropper of 10 ml volume had a unit pack-size of 10. Monthly DIDs were then
102 aggregated by therapeutic group.

103 Total AbC per year was calculated using the formula above by substituting two terms, namely the
104 ‘monthly sale amount’ with the ‘total monthly sales for all four months’ and the ‘days in the month’
105 with a time period of 121 for 2020 and 120 for 2019. To analyse temporal changes, we used a
106 “year-on-year” change (%) metric comparing the “yearly” DID for the first four months of 2020
107 to 2019.

108 AbC pattern was described in terms of proportions (%) of total AbC by therapeutic group for each
109 month. To analyse differences in consumption pattern we used a month-on-month change (%)
110 metric comparing monthly DID per therapeutic group for corresponding months in both years.

111 All analyses were performed on Microsoft Excel; with validation performed on MATLAB.

112 **Results:** The total AbC for January-April was 17.76 DID in 2019 and 15.08 DID in 2020. AbC
113 was dominated by four groups which comprised about 80% of total consumption: J01C, beta-
114 lactams, penicillins; J01D, other beta-lactams; J01F, macrolides; and J01M, quinolones. Overall,
115 the quinolones were most commonly consumed, forming 23-27% of total consumption.


116 The “year-on-year” change was -18.8%, reflecting a drop in consumption of J01 antibiotics for the
 117 first four months of 2020, compared to 2019. Similarly, there was a general drop in month-on-
 118 month consumption across therapeutic groups, except for macrolides and “others” (Table 1).

119
 120 **Table 1. Antibiotic consumption for January-April of 2019 and 2020 in Pakistan expressed**
 121 **as defined daily doses per 1000 inhabitants per day (DID) and month-on-month changes in**
 122 **consumption (see Methods).**

Therapeutic group		Antimicrobial consumption (DDD per 1000 population per day, or DID)		Changes in consumption (%)
		2019	2020	Month-on-month
JO1A Tetracyclines	Jan	2.31	1.96	-15.14
	Feb	2.35	1.90	-19.29
	Mar	2.02	1.44	-28.71
	April	2.12	1.50	-29.17
JO1C Beta-lactams, penicillins	Jan	4.83	3.36	-30.30
	Feb	4.79	3.63	-24.31
	Mar	3.93	3.70	-5.75
	April	3.53	3.18	-9.92
JO1D, Beta-lactams, others	Jan	3.56	3.29	-7.51
	Feb	3.60	3.52	-2.29
	Mar	3.38	3.00	-11.30
	April	3.47	2.36	-31.89
J01F Macrolides	Jan	3.32	3.24	-2.36
	Feb	3.28	3.38	3.26
	Mar	2.91	3.42	17.58
	April	2.67	2.48	-7.14
JO1M Quinolones	Jan	4.75	4.16	-12.42
	Feb	5.05	4.41	-12.67
	Mar	4.52	3.93	-13.00
	April	4.77	3.41	-28.48
Others	Jan	2.15	0.95	-55.62
	Feb	1.70	1.03	-39.23
	Mar	1.12	1.00	-10.47
	April	0.94	1.06	12.62

123

124 In February and March of 2020, macrolides consumption rose by 3 and 18% respectively, while
 125 “others” rose by 13% in April 2020 compared to the same periods in 2019. For macrolides, the
 126 higher consumption, in March 2020, of 3.42 DID from 2.91 in March 2019, meant approximately
 127 112768 additional people consumed the macrolide class per day in the month of March in 2020
 128 compared to 2019; while “others” rose to 1.06 DID in April 2020 from 0.94 DID in 2019 (Figure
 129 1).



130
 131
 132 **Figure 1 Antibiotic consumption patterns for January-April of 2019 and 2020 in Pakistan.**
 133 **2020 consumption was lower for antibiotics for systemic use (ATC J01) during the study**
 134 **period of January-April, except for macrolides which showed a rise for February and March**
 135 **of 2020, and “others” with an increase in April 2020.**

136 Within the macrolides – azithromycin, clarithromycin, clindamycin, erythromycin, lincomycin
 137 and roxithromycin – azithromycin was the most commonly-consumed. In March 2020,
 138 azithromycin contributed 50% to macrolide sale volume with a related consumption of 1.70 DID,

139 compared to 42% of sales and 1.20 DID, in March 2019. Within “others” the rise was driven by
140 increase in the consumption of sulfamethoxazole-trimethoprim.

141 **Discussion:** One of the characteristics of the present outbreak of the COVID-19 pandemic is the
142 general medical uncertainty due to the fact that both the agent (SARS-CoV2) and the disease were
143 completely unknown six months before this study was conducted. Within this context of
144 uncertainty, lack of sound evidence and an unprecedented amount of circulating information, to
145 analyse the consumption of a few antibiotics involved in this information overload is of interest
146 because of the impact of inappropriate consumption on the global AMR threat.

147 This analysis revealed a “year-on-year” drop in total AbC in the first four months of 2020. This
148 may have due to an economic crisis with currency devaluation and price increases that started in
149 2018 and supply chain disruptions from these and border closures with China and India in 2019,
150 coupled with COVID-19 related decrease in outpatient attendance in hospitals (18,19).

151 In contrast, the rise in the consumption of macrolides in March, and, in April 2020, of “others”
152 antibiotics, may have been a result of stock-piling by medicine outlets or clients of azithromycin,
153 following its social-media promotion, alongside chloroquine and hydroxychloroquine, as a
154 preventive or treatment for COVID-19. While “others” also rose, this increase was smaller, being
155 about three orders of magnitude lower.

156 Within the context of COVID-19, three classes of antibacterials are of interest: macrolides,
157 quinolones, and aminoglycosides. In addition to social media promotion, several early guidelines
158 supported the use of these classes based on studies (20–22). Interestingly, macrolides and
159 quinolones are categorized as “Watch” antibiotics according to the WHO AWaRe
160 classification(23). “Watch” antibiotics are first- or second-choice antibiotics indicated for specific,

161 limited number of infections, with the greater potential to induce resistance even with a single use,
162 and, therefore, prioritized as targets of stewardship programs and monitoring. Thus, the observed
163 high levels of use of fluoroquinolones is troubling. Of all Watch therapeutic groups, the
164 fluoroquinolones, which are the most potent inducers of resistance, was the most commonly
165 consumed antimicrobial class during the study period in Pakistan. Another concern raised by the
166 consumption data analysed in this study is that it represented possible use by outpatients of
167 potential treatments (including azithromycin) for secondary bacterial infections in COVID-19 that
168 should be reserved for hospitalized patients.

169 **Conclusion:** This analysis provides relevant evidence for the national antibiotic stewardship
170 program. Overall, the total consumption decreased in the first four months of 2020 compared to
171 the same study period in 2019, possibly arising from a combination of several pre-existing and
172 concurrent economic and health conditions. However, the results suggest an increase in the
173 consumption of the macrolides during the early phase of COVID-19 alongside a high consumption
174 of quinolones, raising concerns about an increased risk of resistance.

175

176 Acknowledgement: We thank PharmEvo (Pvt.) Ltd. for supporting this study with IQVIA data.

177 This work was made possible by support from the Boston University Social Innovation on Drug
178 Resistance (SIDR) Postdoctoral Program to ESFO and the U.S. Pharmacopeial Convention (USP)
179 Quality Institute to CC.

180 Funding: The author(s) received no specific funding for this work.

181 Transparency declarations: None to declare.

182 **References**

183

- 184 1. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in
185 the COVID-19 pandemic. Bull World Health Organ [Internet]. 2020 Jul 1 [cited 2020 Jul
186 2];98(7):442-442A. Available from: [http://www.who.int/entity/bulletin/volumes/98/7/20-](http://www.who.int/entity/bulletin/volumes/98/7/20-268573.pdf)
187 [268573.pdf](http://www.who.int/entity/bulletin/volumes/98/7/20-268573.pdf)
- 188 2. Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-
189 resistant infections and COVID-19. Nat Rev Microbiol [Internet]. 2020 Jun 2 [cited 2020
190 Jul 5];1–2. Available from: <https://www.nature.com/articles/s41579-020-0395-y>
- 191 3. Eynde V, Jacques J. COVID-19: A Brief Overview of the Discovery Clinical Trial.
192 Pharmaceuticals [Internet]. 2020 Apr [cited 2020 Apr 20];13(4):65. Available from:
193 <https://www.mdpi.com/1424-8247/13/4/65>
- 194 4. “Solidarity” clinical trial for COVID-19 treatments [Internet]. [cited 2020 Jul 6]. Available
195 from: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)
196 [on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments)
- 197 5. Soto A. Nigeria Has Chloroquine Poisonings After Trump Praised Drug [Internet].
198 Bloomberg.com. 2020 [cited 2020 Apr 21]. Available from:
199 [https://www.bloomberg.com/news/articles/2020-03-21/nigeria-reports-chloroquine-](https://www.bloomberg.com/news/articles/2020-03-21/nigeria-reports-chloroquine-poisonings-after-trump-praised-drug)
200 [poisonings-after-trump-praised-drug](https://www.bloomberg.com/news/articles/2020-03-21/nigeria-reports-chloroquine-poisonings-after-trump-praised-drug)

- 201 6. Waris A, Atta UK, Ali M, Asmat A, Baset A. COVID-19 outbreak: current scenario of
202 Pakistan. *New Microbes New Infect* [Internet]. 2020 May [cited 2020 Jun 14]; 35:100681.
203 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171524/>
- 204 7. COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2020 Jun
205 14]. Available from: <https://coronavirus.jhu.edu/map.html>
- 206 8. Siddiqui IA | D com | SAS | N. Pakistan confirms first two cases of coronavirus, govt says
207 “no need to panic” [Internet]. DAWN.COM. 2020 [cited 2020 Jul 5]. Available from:
208 <https://www.dawn.com/news/1536792>
- 209 9. Bukhari N, Rasheed H, Nayyer B, Babar Z-U-D. Pharmacists at the frontline beating the
210 COVID-19 pandemic. *J Pharm Policy Pract* [Internet]. 2020 Apr 20 [cited 2020 Jul 5];13.
211 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168565/>
- 212 10. Pakistan’s Lockdown Ended a Month Ago. Now Hospital Signs Read ‘Full.’ [Internet].
213 [cited 2020 Jul 5]. Available from:
214 <https://www.nytimes.com/2020/06/15/world/asia/pakistan-coronavirus-hospitals.html>
- 215 11. WHOCC - ATC/DDD Index [Internet]. [cited 2020 Jun 8]. Available from:
216 https://www.whocc.no/atc_ddd_index/
- 217 12. WHO | 7. Sources of Drug Utilization Data [Internet]. WHO. World Health Organization;
218 [cited 2020 Jul 2]. Available from: [http://www.who.int/medicines/regulation/medicines-](http://www.who.int/medicines/regulation/medicines-safety/toolkit_sources/en/)
219 [safety/toolkit_sources/en/](http://www.who.int/medicines/regulation/medicines-safety/toolkit_sources/en/)
- 220 13. Rieth M. IQVIA Quality Assurance. :137.

- 221 14. World Health Organization. WHO report on surveillance of antibiotic consumption: 2016-
222 2018 early implementation [Internet]. 2018 [cited 2019 Dec 25]. Available from:
223 [https://www.who.int/medicines/areas/rational_use/who-amr-amc-report-](https://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf?ua=1)
224 [20181109.pdf?ua=1](https://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf?ua=1)
- 225 15. Population, total - Pakistan | Data [Internet]. [cited 2020 Jul 16]. Available from:
226 <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=PK>
- 227 16. WHO. Methods to analyse medicine utilization and expenditure to support pharmaceutical
228 policy implementation [Internet]. Geneva; 2018 [cited 2020 Jul 8]. Available from:
229 <https://apps.who.int/iris/bitstream/handle/10665/274282/9789241514040-eng.pdf?ua=1>
- 230 17. Li G, Jackson C, Bielicki J, Ellis S, Hsia Y, Sharland M. Global sales of oral antibiotics
231 formulated for children. Bull World Health Organ [Internet]. 2020 Jul 1 [cited 2020 Jul
232 2];98(7):458–66. Available from: [http://www.who.int/entity/bulletin/volumes/98/7/19-](http://www.who.int/entity/bulletin/volumes/98/7/19-235309.pdf)
233 [235309.pdf](http://www.who.int/entity/bulletin/volumes/98/7/19-235309.pdf)
- 234 18. Pakistan’s consumer sector earnings dip 26% in 2019 [Internet]. The Express Tribune. 2020
235 [cited 2020 Jul 8]. Available from: [http://tribune.com.pk/story/2178962/2-pakistans-](http://tribune.com.pk/story/2178962/2-pakistans-consumer-sector-earnings-dip-26-2019)
236 [consumer-sector-earnings-dip-26-2019](http://tribune.com.pk/story/2178962/2-pakistans-consumer-sector-earnings-dip-26-2019)
- 237 19. Junaidi I. Recent increase in drug prices capped at 75pc [Internet]. DAWN.COM. 2019
238 [cited 2020 Jul 15]. Available from: <https://www.dawn.com/news/1482743>
- 239 20. Rapidly managing pneumonia in older people during a pandemic [Internet]. CEBM. [cited
240 2020 Jul 1]. Available from: [https://www.cebm.net/covid-19/rapidly-managing-pneumonia-](https://www.cebm.net/covid-19/rapidly-managing-pneumonia-in-older-people-during-a-pandemic/)
241 [in-older-people-during-a-pandemic/](https://www.cebm.net/covid-19/rapidly-managing-pneumonia-in-older-people-during-a-pandemic/)

- 242 21. Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershman AA, Kamal MA, et al.
243 Therapeutic management of patients with COVID-19: a systematic review. *Infection*
244 *Prevention in Practice* [Internet]. 2020 Sep [cited 2020 Jul 5];2(3):100061. Available from:
245 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162768/>
- 246 22. I K, M D. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to
247 Be Beneficial as an Adjunct Treatment in COVID-19? [Internet]. *Archives of medical*
248 *research. Arch Med Res*; 2020 [cited 2020 Jul 5]. Available from:
249 <https://pubmed.ncbi.nlm.nih.gov/32546446/>
- 250 23. World Health Organization. The 2019 WHO AWaRe classification of antibiotics for
251 evaluation and monitoring of use [Internet]. World Health Organization; 2019 [cited 2020
252 Jul 2]. Report No.: WHO/EMP/IAU/2019.11. Available from:
253 <https://apps.who.int/iris/handle/10665/327957>
- 254